A E Panerai

Publications (3)7.16 Total impact

• Article: PPADS, a purinergic antagonist reduces Fos expression at spinal cord level in a mouse model of mononeuropathy.

  E Borsani, R Albertini, M Colleoni, P Sacerdote, A E Trovato, C Lonati, M Labanca, A E Panerai, R Rezzani, L F Rodella
  [show abstract] [hide abstract]
  ABSTRACT: Recent evidence suggest that ATP plays a role as an endogenous pain mediator generating and/or modulating pain signaling from the periphery to the spinal cord. In this study we evaluated the effects of intraperitoneal administration of P2 receptor antagonist, pyridoxalphosphate-6-azophenyl-2',4'-disulphonic acid (PPADS), evaluating pain related behaviours and monitoring the expression of Fos, a marker of activated neurons, in an experimental mouse model of neuropathic pain (sciatic nerve tying). The PPADS administration decreased both tactile allodynia and thermal hyperalgesia in a time and dose dependent manner. The dose of 25 mg/kg PPADS completely reversed nociceptive hypersensitivity. Moreover, non-noxious stimulation induced an increase of Fos positive neurons in the spinal cord of animals with tying of sciatic nerve. PPADS administration partially reversed this increase. These results suggest that PPADS reduces neuronal activation at spinal cord level and that P2 receptors are involved in the retrograde signalling progress exciting sensory spinal neurons.
  Brain Research 04/2008; 1199:74-81. · 2.73 Impact Factor
• Article: Catecholamine and serotonin depletion from rat spinal cord: effects on morphine and footshock induced analgesia.

  M O Carruba, E Nisoli, V Garosi, P Sacerdote, A E Panerai, M Da Prada
  [show abstract] [hide abstract]
  ABSTRACT: Using a methodology that causes a selective degeneration of spinal cord catecholaminergic or serotoninergic pathways but not those of the brain, it has been possible to study more precisely the role played by the spinal cord monoaminergic systems that underly the mechanism through which morphine and endogenous opioids modulate nociceptive inputs. Both noradrenaline (NA) and serotonin (5-HT) appear to be involved: first, the noradrenergic and only subsequently, with higher doses of the opiate, the serotoninergic pathways.
  Pharmacological Research 25(2):187-94. · 4.44 Impact Factor
• Article: PPADS, a purinergic antagonist reduces Fos expression at spinal cord level in a mouse model of mononeuropathy

  E. Borsani, R. Albertini, M. Colleoni, P. Sacerdote, A.E. Trovato, C. Lonati, M. Labanca, A.E. Panerai, R. Rezzani, L.F. Rodella
  [show abstract] [hide abstract]
  ABSTRACT: Recent evidence suggest that ATP plays a role as an endogenous pain mediator generating and/or modulating pain signaling from the periphery to the spinal cord. In this study we evaluated the effects of intraperitoneal administration of P2 receptor antagonist, pyridoxalphosphate-6-azophenyl-2′,4′-disulphonic acid (PPADS), evaluating pain related behaviours and monitoring the expression of Fos, a marker of activated neurons, in an experimental mouse model of neuropathic pain (sciatic nerve tying). The PPADS administration decreased both tactile allodynia and thermal hyperalgesia in a time and dose dependent manner. The dose of 25 mg/kg PPADS completely reversed nociceptive hypersensitivity. Moreover, non-noxious stimulation induced an increase of Fos positive neurons in the spinal cord of animals with tying of sciatic nerve. PPADS administration partially reversed this increase. These results suggest that PPADS reduces neuronal activation at spinal cord level and that P2 receptors are involved in the retrograde signalling progress exciting sensory spinal neurons.
  Brain Research.